etidronate has been researched along with Atherogenesis in 4 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, an inverse dose-response relationship was seen, with an increased risk in those with low adherence (≤0." | 1.38 | Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? ( Vestergaard, P, 2012) |
| "Atherosclerotic plaque formation and vascular calcinosis were modeled in a subchronic experiment." | 1.38 | Biochemical indicators of atherogenic and protective activity of xydiphone in experimental animals. ( Dreval, AA; Ilyushina, IA; Murashov, AN; Pimenov, MS; Sukhorukov, VS; Yur'eva, EA, 2012) |
| "Thirteen Japanese type 2 diabetes postmenopausal women with newly diagnosed osteoporosis (osteoporosis group) and 13 age- and weight-matched diabetic women with normal bone mineral density (control group) were enrolled in this 1-year prospective study." | 1.36 | Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. ( Hayashi, K; Kanazawa, I; Shimizu, T; Sugimoto, T; Takase, H; Yamaguchi, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Hayashi, K | 1 |
| Takase, H | 1 |
| Shimizu, T | 1 |
| Sugimoto, T | 1 |
| Vestergaard, P | 1 |
| Yur'eva, EA | 1 |
| Sukhorukov, VS | 1 |
| Murashov, AN | 1 |
| Pimenov, MS | 1 |
| Ilyushina, IA | 1 |
| Dreval, AA | 1 |
| Grases, F | 1 |
| Sanchis, P | 1 |
| Perelló, J | 1 |
| Isern, B | 1 |
| Prieto, RM | 1 |
| Fernández-Palomeque, C | 1 |
| Torres, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications[NCT01000233] | Phase 2/Phase 3 | 250 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for etidronate and Atherogenesis
| Article | Year |
|---|---|
Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis.
Topics: Aged; Aorta, Abdominal; Atherosclerosis; Body Mass Index; Bone Density Conservation Agents; Calcinos | 2010 |
Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
Topics: Aged; Alendronate; Atherosclerosis; Bone Density Conservation Agents; Calcium; Cohort Studies; Dipho | 2012 |
Biochemical indicators of atherogenic and protective activity of xydiphone in experimental animals.
Topics: Alkaline Phosphatase; Animals; Atherosclerosis; Biomarkers; Cholesterol, LDL; Creatine Kinase; Creat | 2012 |
Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats.
Topics: Animals; Aorta; Atherosclerosis; Bone Density Conservation Agents; Calcinosis; Calcium; Crystallizat | 2007 |